-- Patients to Benefit From Easy-to-Use Inhaler With Enhanced Drug Delivery Boehringer Ingelheim and Pfizer today announced successful completion of the approval process for authorisation to market ...

RIDGEFIELD, Conn. & NEW YORK--(BUSINESS WIRE)--A new study, published today in The New England Journal of Medicine (NEJM), showed that SPIRIVA ® HandiHaler ® (tiotropium bromide inhalation powder), a ...

Boehringer Ingelheim’s Spiriva — a drug approved for emphysema and chronic lung conditions — was shown to be just as effective as GlaxoSmithKline’s asthma drug Serevent and more effective than a ...

Spiriva’s “Controlling the Elephant” campaign is one of the most brilliant we’ve seen in ages. It’s a perfect execution, and, in my view, delivers on the adage that it is better to have one big idea ...

Major League Baseball’s annual All-Star Game last night featured new DTC spots for Spiriva HandiHaler, an inhaler indicated for chronic bronchitis and emphysema. The television spots were created by ...

Pfizer and Boehringer Ingelheim have been boosted by the news that experts in the USA have recommended expanding the label on their chronic obstructive pulmonary disease blockbuster Spiriva. fizer and ...

RIDGEFIELD, Conn., March 29, 2018 /PRNewswire/ -- Boehringer Ingelheim announced today that data from the DYNAGITO trial, a 52-week study involving more than 7,800 people across a broad range of COPD ...

Post hoc analyses of some Phase 3 placebo-controlled studies showed that adding Spiriva Respimat improved peak FEV1(0-3h) and trough FEV1 across a range of baseline IgE levels and eosinophil counts.